Bullish Case: MOH has rebounded +38.8% YoY and +6.5% over the month, with call volume 81% above puts and bullish risk 33% higher than bearish. Helium's density peaks near $210 versus the market's $200, and the CEO cites Medicaid work-rule benefits. Helium IV (37.8 Nov) runs ~16 pts below market (53.9), implying near-dated downside premium is rich—if MCR stabilizes and the post-midterm healthcare backdrop holds, IV compression supports a grind toward $215-$220.

Bearish Case: Near-dated market IV is backwardated (53.9% Nov vs 46.9% Jan) with puts like the 210P at 123% IV pricing a hard left tail; Helium's own surface shows 68%+ IV at low strikes for ~21 days ahead. Q3 MCR printed 92.2%, the $1B MAPD exit removes premium, Medicaid is 75% of revenue, and OBBBA cuts ~$911B from Medicaid spending. Helium's forecast correlation is -0.2, so momentum signals offer little edge.

Potential Outcomes:

1. 35% — Post-election drift + IV crush: price $205-$225 as Nov IV (53.9→ Helium 37.8) compresses; falsified by realized vol staying >45%.
2. 25% — Chop/sideways $195-$215; mean-reverting price with 10th-percentile volume; no MCR catalyst until Q4 print.
3. 20% — MCR >93% or Q4 guidance cut → -$8-12%, put skew steepens.
4. 10% — Medicaid work-rule rate benefit confirmed → +5-8% above $220.
5. 7% — Regulatory 8-K/reserve writedown → <$180 tail spike.
6. 3% — SPY risk-off amplifies -5-10% drawdown.

November 05, 2026